This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
BioMarin Pharmaceutical Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
BioMarin Pharmaceutical has a total shareholder equity of $4.9B and total debt of $1.1B, which brings its debt-to-equity ratio to 22.2%. Its total assets and total liabilities are $6.8B and $1.9B respectively. BioMarin Pharmaceutical's EBIT is $120.0M making its interest coverage ratio -3.5. It has cash and short-term investments of $1.1B.
Anahtar bilgiler
22.2%
Borç/özkaynak oranı
US$1.09b
Borç
| Faiz karşılama oranı | -3.5x |
| Nakit | US$1.13b |
| Eşitlik | US$4.90b |
| Toplam yükümlülükler | US$1.86b |
| Toplam varlıklar | US$6.76b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: BM8's short term assets ($3.0B) exceed its short term liabilities ($1.2B).
Uzun Vadeli Yükümlülükler: BM8's short term assets ($3.0B) exceed its long term liabilities ($698.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: BM8 has more cash than its total debt.
Borcun Azaltılması: BM8's debt to equity ratio has reduced from 41.2% to 22.2% over the past 5 years.
Borç Kapsamı: BM8's debt is not well covered by operating cash flow (12.8%).
Faiz Kapsamı: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.